BCRX  Biocryst Pharmaceuticals Inc.

Exchange

NASDAQ

Sector

Health Care

Industry

Biotechnology: Biological Products (No Diagnostic Substances)

Market Cap.

329.75M

Vuru Grade

23.50/100

Current Price

$4.10
+0.00 (+0.00%)

Company Metrics

  • P/E 0
  • P/S 11.26
  • P/B 13.71
  • EPS -0.62
  • Cash ROIC -144.97%
  • Cash Ratio 1.01
  • Dividend 0 / 0%
  • Avg. Vol. 1.51M
  • Shares 80.43M
  • Market Cap. 329.75M

Company Description

BioCryst Pharmaceuticals, Inc. designs, optimizes, and develops small-molecule pharmaceuticals that block key enzymes involved in infectious diseases, cancer, and inflammatory diseases. It uses structure-based drug design, which incorporates multiple scientific disciplines, including biology, crystallography, medicinal chemistry, and computer modeling to develop new therapeutic candidates. The com... more


Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow

News

The Reason Behind BioCryst Pharmaceuticals, Inc.'s 12% Pop Higher
Motley Fool - Mar 8, 2017
Shares of BioCryst Pharmaceuticals (NASDAQ:BCRX), a biotech company that develops small-molecule drugs to block enzymes involved in disease proliferation, surged as much as 12% today after a report was issued that a highly pathogenic H5N1 bird flu ...
BioCryst Pharmaceuticals Commences Public Offering of Common Stock - GlobeNewswire (press release)
Trading Options During Earnings in BioCryst Pharmaceuticals Inc
CML News - 16 hours ago
We're going to examine buying and selling out of the money strangles in BioCryst Pharmaceuticals Inc and find out once and for all what the winning trades have been during earnings releases.
Robert A. Ingram Named Chairman of BioCryst Pharmaceuticals, Inc.
GlobeNewswire (press release) - May 30, 2017
RESEARCH TRIANGLE PARK, N.C., May 30, 2017 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) announced today the appointment of Robert A. Ingram as Chairman of its Board of Directors.
Taking a Look at the Data Behind BioCryst Pharmaceuticals, Inc. (BCRX) - StockNewsJournal
BAKER BROS. ADVISORS LP is the biggest holder of BioCryst Pharmaceuticals, Inc ... - Post Analyst
BioCryst: Frustration Then Joy In Biotech Investing
Seeking Alpha - May 31, 2017
BioCryst Pharmaceuticals (NASDAQ:BCRX) has had a frustrating few months, with a progressive decline in share price since mid-March of this year (after $48 million net proceeds of equity raising).
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Sees Significantly Lower Trading ...
Modern Readers - Aug 18, 2017
BioCryst Pharmaceuticals, Inc. shares had a trading volume of 521K in the last trading session. Shares saw a steep decrease in trading volume of 88.46% under the normal average daily volume.
Eagle Bulk Shipping Inc. (NasdaqGS:EGLE) and BioCryst Pharmaceuticals, Inc ...
Melville Review - 20 hours ago
Eagle Bulk Shipping Inc. (NasdaqGS:EGLE) currently has a Value Composite score of 65. Similarly, the Value Composite Two (VC2) is calculated with the same ratios, but adds the Shareholder Yield.
Trading Earnings Optimism With Options in BioCryst Pharmaceuticals Inc
CML News - Aug 12, 2017
There is a powerful pattern of optimism and momentum in BioCryst Pharmaceuticals Inc (NASDAQ:BCRX) stock right before of earnings, and we can capture that pattern by looking at returns in the option market.
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Reports Initiation Of ZENITH-1
WallStreetPR - Aug 11, 2017
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) reported the dosing of the first subject into its clinical study of ZENITH-1.
What the Chart Means for BioCryst Pharmaceuticals, Inc. (BCRX) - Economic News
UBS Asset Management Americas Inc. Purchases Shares of 46669 BioCryst ... - BNB Daily (blog)
BioCryst reverses premarket, down 24%
Seeking Alpha - Feb 27, 2017
The modest premarket bump in BioCryst Pharmaceuticals (NASDAQ:BCRX) after it reported positive interim data on BCX7353 is a distant memory.
BioCryst Reports Fourth Quarter and Full Year 2016 Financial Results - GlobeNewswire (press release)
An intrinsic value calculation for BioCryst Pharmaceuticals Inc (BCRX) shows ...
Simply Wall St - Aug 7, 2017
How far off is BioCryst Pharmaceuticals (NASDAQ:BCRX) to its intrinsic value? I am going to take a look now by estimating the Future Cash Flows and discounting them to their present value.
Growth Rate Assumed by Market

We did a reverse valuation to calculate the growth rate the market is assuming for BCRX to be considered fairly valued at its current market price. It's useful to compare this to the growth rate we're assuming for the Growth Price.

Future Free Cash Flow Growth Rate

This is the annual growth rate we've applied to calculate BCRX's Free Cash Flow for the next 10 years. To calculate it, we looked at several time periods of the last 10 years. Feel free to adjust it, but we limit the initial growth rate to 20% and slow it down over the years. Otherwise, long-term sustainability issues come into play.

Discount Rate

The discount rate is the annual rate of return an investor requires to take the risk of investing in a single stock. To account for that risk, this should be above 8-10%, as this is the avg. annual rate of return for the S&P500 over the past 100 years.

$4.10 Current Price

$-4.68 Growth Price (DCF)

Why is this negative?


Show Free Cash Flow numbers

$-1.72 Book Price

Overvalued by 141.94%


Very Poor Cash Return on Invested Capital over the past 5 years

BCRX has failed to generate positive returns on its investments in buildings, projects and equipment. This could be due to poor management, lack of an economic moat or the capital intensive nature of the business.

BCRX has lost $144.97 of cash for every $100 invested.
Figures in USD. Fiscal year ends in December
20122013201420152016
Free Cash Flow -37.51M -26.56M -38.66M -18.24M -58.72M
divided by
Invested Capital 4.62M -4.45M 6.42M 8.54M -19.16M
Cash ROIC -812.61% 597.53% -602.60% -213.58% 306.40%

Very Poor Return on Equity over the past 5 years

BCRX has shown an inability to deliver results for shareholders. This could be due to poor management, BCRX operating in a highly competitive industry, or having a weak business in general.

BCRX has generated a $728.89 loss for every $100 of Shareholders' Equity.
Figures in USD. Fiscal year ends in December
20122013201420152016
Net Income -39.08M -30.11M -45.19M -43.02M -55.14M
divided by
Stockholders' Equity -454,000.00 -1.13M 75.64M 47.72M 1.58M
Return on Equity - - -59.75% -90.14% -3,494.55%

Poor Business Performance over the past 10 years

BCRX's inability to produce positive free cash flow for the majority of the past 10 years is concerning. It should be a red flag, since this company does not have a track record of delivering results for shareholders. This could be due to poor management or the nature of its business.

BCRX has been losing money for the majority of the past 10 years.
Figures in USD. Fiscal year ends in December
2007200820092010201120122013201420152016
Free Cash Flow -25.00M -22.09M -16.82M -28.88M -32.31M -37.51M -26.56M -38.66M -18.24M -58.72M

Weak Balance Sheet

BCRX's financial position is not ideal. The key is to check whether BCRX is using debt to fuel its growth and the sustainability of that tendency. Highly capital intensive businesses (see Economic Moat) follow this route, which can deeply impact the future prospects of the business.
Figures in USD. Fiscal year ends in December
2007200820092010201120122013201420152016
Cash 50.70M 61.53M 68.96M 53.95M 41.72M 35.60M 38.06M 72.77M 51.56M 54.65M
Current Assets 91.70M 75.02M 111.02M 87.42M 52.86M 41.98M 42.12M 89.34M 65.99M 66.99M
Total Assets 142.72M 84.69M 142.19M 109.45M 82.21M 57.44M 48.87M 136.87M 124.56M 89.85M
Current Liabilities 28.12M 17.11M 37.25M 27.82M 26.30M 17.22M 15.26M 57.69M 64.45M 54.36M
Total Liabilities 77.81M 38.27M 55.92M 43.94M 67.40M 57.89M 49.99M 61.24M 76.83M 88.27M
Stockholder' Equity 64.91M 46.43M 86.27M 65.50M 14.81M -454,000.00 -1.13M 75.64M 47.72M 1.58M
Current Ratio 3.26 4.39 2.98 3.14 2.01 2.44 2.76 1.55 1.02 1.23
TL-to-TA 0.55 0.45 0.39 0.40 0.82 1.01 1.02 0.45 0.62 0.98

Low or No Reinvestment of Profits over the past 10 years

BCRX has either been retaining a small amount of their earnings or has done so inconsistently. A lack of consistency could be due to BCRX operating at a loss or them having such a strong economic moat they feel comfortable spending profits on growth. Be wary of future prospects and if applicable, inspect the moat's sustainability.
Figures in USD. Fiscal year ends in December
2007200820092010201120122013201420152016
Retained Earnings -224.54M -249.27M -262.72M -296.57M -353.52M -392.60M -422.71M -467.90M -510.92M -566.06M
Retained Earnings Growth - -11.01% -5.40% -12.89% -19.20% -11.05% -7.67% -10.69% -9.19% -10.79%

Erratic Net Profit Margins over the past 10 years

BCRX has had highly erratic net profit margins which are a great cause for concern. This company may operate in a highly volatile industry, or it may just have poor performance. Look at reasons for this inconsistency to understand if there is any reason to look past it.
Figures in USD. Fiscal year ends in December
2007200820092010201120122013201420152016
Net Income -29.06M -24.73M -13.45M -33.85M -56.95M -39.08M -30.11M -45.19M -43.02M -55.14M
divided by
Revenue 71.24M 56.56M 74.59M 62.38M 19.64M 26.29M 17.33M 13.61M 48.26M 26.35M
Net Profit Margin -40.79% -43.73% -18.03% -54.27% -289.91% -148.64% -173.72% -332.08% -89.15% -209.25%

Strong Pricing Power over the past 10 years

BCRX has maintained substantial gross margins, suggesting that they have been able to set prices without consideration of the cost of goods sold. This potentially leaves flexibility in inflationary environments to raise prices on consumers and maintain profitability.

$97.76 of every $100 worth of sales have been Gross Profit, on average over the past 10 years.
Figures in USD. Fiscal year ends in December
2007200820092010201120122013201420152016
Gross Profit 71.24M 56.56M 70.05M 62.29M 19.64M 26.16M 17.23M 13.49M 46.36M 23.65M
divided by
Revenue 71.24M 56.56M 74.59M 62.38M 19.64M 26.29M 17.33M 13.61M 48.26M 26.35M
Gross Margin 100.00% 100.00% 93.91% 99.86% 100.00% 99.50% 99.43% 99.10% 96.07% 89.76%

Low Capital Intensity over the past 10 years

BCRX has consistently used a small portion of their Net Income buying new equipment or investing in new facilities. This indicates that BCRX may require minimal investment to stay competitive. This leaves them with extra money to spend on growing their business and potentially buying back stock.

-% of Profits are being spent on Capital Expenditures, like Property, Plant, & Equipment, required to run the business.
Figures in USD. Fiscal year ends in December
2007200820092010201120122013201420152016
Capital Expenditure - 1.21M 603,692.00 324,764.00 55,000.00 113,000.00 30,000.00 106,000.00 5.12M 5.28M
divided by
Net Income -29.06M -24.73M -13.45M -33.85M -56.95M -39.08M -30.11M -45.19M -43.02M -55.14M
Capital Expenditure Ratio - -4.90% -4.49% -0.96% -0.10% -0.29% -0.10% -0.23% -11.91% -9.57%

No Dividend History over the past 10 years

BCRX has never distributed dividends or has recently suspended their dividend distribution.
Figures in USD. Fiscal year ends in December
2007200820092010201120122013201420152016
Dividend Paid - - - - - - - - - -
divided by
Shares Outstanding 32.77M 38.06M 38.93M 44.56M 45.14M 49.47M 55.22M 66.77M 72.90M 73.70M
Dividend Paid Per Share - - - - - - - - - -
Price at Year End 5.89 1.19 6.44 5.13 2.47 1.40 7.64 12.10 10.49 6.33
Dividend Yield - - - - - - - - - -

No History of Stock Buybacks over the past 10 years

We're neutral on this. It's not necessarily good or bad that BCRX hasn't initiated a stock buyback.
Figures in USD. Fiscal year ends in December
2007200820092010201120122013201420152016
Shares Outstanding 32.77M 38.06M 38.93M 44.56M 45.14M 49.47M 55.22M 66.77M 72.90M 73.70M
Stock Bought Back - -13.90% -2.22% -12.65% -1.28% -8.75% -10.40% -17.31% -8.41% -1.08%
Share your thoughts about BCRX

Sign Up or Log In to start contributing!


Discussion

Nothing here yet. Be the first to post!